Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human FCGR3A / CD16a (F176) Protein, His tag, 1mg  

Recombinant Human FCGR3A / CD16a (F176) Protein, His tag, 1mg

Human FCGR3A / CD16a (F176) Protein (Gly 17 - Gln 208), was produced in human 293 cells (HEK293), His tag

Synonym
recombinant, human, protein, FCGR3A, CD16A, FCG3, FCGR3, IGFR3

More details

CDA-H5220-1K

Availability: within 7 days

1 800,00 €

Background
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Source
Recombinant Human FCGR3A / CD16a (F176) Protein, also called Human FCGR3A /CD16a Protein (176 Phe), Gly 17 - Gln 208 (Accession # P08637-1), was produced in human 293 cells (HEK293) at ACROBiosystems.
Predicted N-terminus: Gly 17
Request for sequence

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 23.7 kDa. The protein migrates as 39-51 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Human FCGR3A / CD16a (F176), His Tag (Cat. No. CDA-H5220) ELISA bioactivity
(1) Immobilized Anti-CTLA4 /CD152, Human IgG1 at 5 μg/mL (100 μL/well) can bind Human CD16a, His Tag (Cat. No. CDA-H5220) with a linear range of 2.5-20 μg/mL (QC tested).
(2) The bioactivity is measured by its binding ability to Herceptin mAb in a SPR assay. Immobilized Human FCGR3A / CD16a (F176), His Tag (Cat. No. CDA-H5220) can bind trastuzumab with affinity constant of around 1.8 uM (Routinely tested).

References

(1)Webster NL., et al., 2006, J Leukoc Biol. 79: 294-302.
(2)Nagarajan S., et al., 1995, J Biol Chem. 270: 25762-70.
(3)Ravetch JV., 1989, J. Exp. Med. 170:481.